Alzamend Neuro
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell Alzamend Neuro and other ETFs, options, and stocks.About ALZN
Alzamend Neuro, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001, which is in Phase II clinical trial, and delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bipolar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders, and AL002, which completed preclinical stage, and uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease.
ALZN Key Statistics
Stock Snapshot
With a market cap of 6.95M, Alzamend Neuro(ALZN) trades at $1.31. The stock has a price-to-earnings ratio of -0.45.
On 2026-08-02, Alzamend Neuro(ALZN) stock moved within a range of $1.29 to $1.36. With shares now at $1.31, the stock is trading +1.6% above its intraday low and -3.7% below the session's peak.
Trading volume for Alzamend Neuro(ALZN) stock has reached 24.81K, versus its average volume of 42.01K.
The stock's 52-week range extends from a low of $0.84 to a high of $2.68.
The stock's 52-week range extends from a low of $0.84 to a high of $2.68.
ALZN News
Alzamend Neuro, Inc. (ALZN) announced an update on their ongoing clinical study. Unlock powerful investing tools with TipRanks Premium to make smarter, more co...
People also own
Similar Marketcap
This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.
Popular Stocks
This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset
Newly Listed
This list is generated by showing companies that recently went public.